Trial Profile
Eltrombopag in Patients with Newly Diagnosed, Persistent, and Chronic Immune Thrombocytopenia (ITP) a real world setting in the US.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology